Related scientific articles (all)

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Authors : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Year : 2012
Journal : Oncogene
Volume : 31(31)
Pages : 3569-83

Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.

Authors : Zardavas D, Bozovic-Spasojevic I, de Azambuja E
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 612-22

Proteomic changes associated with breast cancer progression in the MCF10AT model.

Authors : Fumagalli D, Michiels S, Sotiriou C
Year : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pages : 9-10

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

Authors : Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L
Year : 2011
Journal : Support Care Cancer
Volume : 19(7)
Pages : 1001-8

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Authors : Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM
Year : 2011
Journal : Eur. J. Heart Fail.
Volume : 13(1)
Pages : 1-10

A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer.

Authors : Fumagalli D, Michiels S, Sotiriou C
Year : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pages : 10

Motherhood after breast cancer: searching for la dolce vita.

Authors : Azim HA, Peccatori FA, de Azambuja E, Piccart-Gebhart M
Year : 2011
Journal : Expert Rev Anticancer Ther
Volume : 11(2)
Pages : 287-98

Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model.

Authors : Fumagalli D, Michiels S, Sotiriou C
Year : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pages : 11

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Authors : Bozovic-Spasojevic I, Azim HA, Paesmans M, Suter T, Piccart-Gebhart M, de Azambuja E
Year : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pages : 209-11

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Authors : Fumagalli D, Michiels S, Sotiriou C
Year : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pages : 12-3

Multifactorial approach to predicting resistance to anthracyclines.

Authors : Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L
Year : 2011
Journal : J. Clin. Oncol.
Volume : 29(12)
Pages : 1578-86

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Authors : Filho OM, Ignatiadis M, Sotiriou C
Year : 2011
Journal : Crit Rev Oncol Hematol
Volume : 77(1)
Pages : 20-9

Breast cancer: Should we assess HER2 status by Oncotype DX?

Authors : Ignatiadis M, Sotiriou C
Year : 2011
Journal : Nat Rev Clin Oncol
Volume : 9(1)
Pages : 12-4

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

Authors : Azim HA, de Azambuja E, Colozza M, Bines J, Piccart-Gebhart M
Year : 2011
Journal : Ann Oncol
Volume : 22(9)
Pages : 1939-47

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Authors : Saini KS, Azim HA, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2011
Journal : Breast
Volume : 20 Suppl 3
Pages : S20-7

Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?

Authors : Piccart-Gebhart M, Viale G, Ellis P, Abramowicz M, Carey L
Year : 2011
Journal : Ecancermedicalscience
Volume : 5(null)
Pages : 217

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

Authors : Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart-Gebhart M
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(6)
Pages : 547-58

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors : Bonnefoi H, Piccart-Gebhart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R
Year : 2011
Journal : Lancet Oncol
Volume : 12(6)
Pages : 527-39

Improving quality of life after breast cancer: dealing with symptoms.

Authors : Pinto AC, de Azambuja E
Year : 2011
Journal : Maturitas
Volume : 70(4)
Pages : 343-8

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Authors : Gianni L, Dafni U, Gelber Rd, de Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart M, Bell R
Year : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pages : 236-44